摘要
目的探讨培菲康配合四联疗法在幽门螺杆菌(Hp)感染相关性慢性胃炎患者中的作用。方法选取周口市第二人民医院2021年2月至2022年4月收治的116例Hp感染相关性慢性胃炎患者作为研究对象,利用随机数字表法分为观察组(58例)与对照组(58例)。对照组给予四联疗法治疗,观察组给予培菲康配合四联疗法治疗,两组均治疗两周。比较两组患者临床治疗效果,Hp根除率和复发率,治疗前后胃肠激素水平和血清炎症因子水平以及不良反应。结果治疗后观察组Hp根除率高于对照组(P<0.05),复发率低于对照组(P<0.05);治疗后两组患者临床效果比较,差异有统计学意义(P<0.05),观察组总有效率高于对照组(P<0.05);治疗后两组患者胃泌素(GAS)、胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)、肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)水平均较治疗前降低(P<0.05),但观察组以上指标水平均低于对照组(P<0.05);两组患者不良反应比较,差异无统计学意义(P<0.05)。结论培菲康配合四联疗法有助于提高Hp感染相关性慢性胃炎患者的治疗效果和Hp根除率,降低复发率,改善胃肠激素水平和血清炎症因子水平,且安全性良好。
【Objective】To explore the role of Peifeikang combined with quadruple therapy in patients with chronic gastritis associated with Helicobacter pylori(Hp)infection.【Methods】Totally 116 cases of chronic gastritis associated with Hp infection treated in our hospital from February 2021 to April 2022 were selected as the research objects,and they were divided into observation group(58 cases)and control group(58 cases)by random number table.The control group was treated with quadruple therapy,and the observation group was treated with Peifeikang combined with quadruple therapy,and both groups were treated for two weeks.The clinical treatment effect,Hp eradication rate and recurrence rate,gastrointestinal hormone levels and serum inflammatory factor levels before and after treatment,and adverse reactions were compared between the two groups.【Results】The eradication rate of Hp in the observation group was higher than that in the control group after treatment(P<0.05),and the recurrence rate was lower than that in the control group(P<0.05).There was a statistically significant difference in the distribution of clinical effects between the two groups after treatment(P<0.05),and the total effective rate of the observation group was higher than that of the control group(P<0.05).The levels of gastrin(GAS),pepsinogen I(PG-I),pepsinogen II(PG-II),tumor necrosis factor(TNF-α),interleukin-6(IL-6),interleukin-8(IL-8)in both groups decreased after treatment(P<0.05),but the levels of the above indexes in the observation group were lower than those in the control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P<0.05).【Conclusion】Peifeikang combined with quadruple therapy is helpful to improve the therapeutic effect and Hp eradication rate of patients with Hp infection related chronic gastritis,reduce the recurrence rate,improve the levels of gastrointestinal hormones and serum inflammatory factors,and has good safety.
作者
闫向阳
袁媛
殷博迪
YAN Xiangyang;YUAN Yuan;YIN Bodi(Pharmacy Department,the Second People's Hospital of Zhoukou,Zhoukou,Henan 466000,China;Western Medicine Room,the Second People's Hospital of Zhoukou,Zhoukou,Henan 466000,China)
出处
《中国医学工程》
2023年第5期119-123,共5页
China Medical Engineering
关键词
培菲康
四联疗法
幽门螺杆菌
慢性胃炎
Peifeikang
quadruple therapy
helicobacter pylori
chronic gastritis
